Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015 (2015), Article ID 902137, 8 pages
http://dx.doi.org/10.1155/2015/902137
Research Article

Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy

1The Ella Lemelbaum Institute for Melanoma, Sheba Medical Center, 52621 Tel Hashomer, Israel
2Talpiot Medical Leadership Program, Sheba Medical Center, 52621 Tel Hashomer, Israel
3Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, 69102 Tel Aviv, Israel

Received 16 July 2015; Revised 8 October 2015; Accepted 15 October 2015

Academic Editor: Roberta Castriconi

Copyright © 2015 R. Ortenberg et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Karagiannis, M. Fittall, and S. N. Karagiannis, “Evaluating biomarkers in melanoma,” Frontiers in Oncology, vol. 4, article 383, 2014. View at Publisher · View at Google Scholar
  2. A. C. Geller, R. W. Clapp, A. J. Sober et al., “Melanoma epidemic: an analysis of six decades of data from the connecticut tumor registry,” Journal of Clinical Oncology, vol. 31, no. 33, pp. 4172–4178, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Shtivelman, M. A. Davies, P. Hwu et al., “Pathways and therapeutic targets in melanoma,” Oncotarget, vol. 5, no. 7, pp. 1701–1752, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Sapoznik, O. Hammer, R. Ortenberg et al., “Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms,” Clinical and Developmental Immunology, vol. 2012, Article ID 818214, 9 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Deichmann, A. Benner, M. Bock et al., “S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma,” Journal of Clinical Oncology, vol. 17, no. 6, pp. 1891–1896, 1999. View at Google Scholar · View at Scopus
  6. M. Deichmann, B. Kahle, K. Moser, J. Wacker, and K. Wüst, “Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase,” British Journal of Cancer, vol. 91, no. 4, pp. 699–702, 2004. View at Google Scholar · View at Scopus
  7. S. D. Gray-Owen and R. S. Blumberg, “CEACAM1: contact-dependent control of immunity,” Nature Reviews Immunology, vol. 6, no. 6, pp. 433–446, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Kuespert, S. Pils, and C. R. Hauck, “CEACAMs: their role in physiology and pathophysiology,” Current Opinion in Cell Biology, vol. 18, no. 5, pp. 565–571, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Sapoznik, R. Ortenberg, J. Schachter, and G. Markel, “CEACAM1 in malignant melanoma: a diagnostic and therapeutic target,” Current Topics in Medicinal Chemistry, vol. 12, no. 1, pp. 3–10, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Ortenberg, “Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactions,” Molecular Cancer Therapeutics, vol. 11, no. 6, pp. 1300–1310, 2012. View at Publisher · View at Google Scholar
  11. M. Neumaier, S. Paululat, A. Chan, P. Matthaes, and C. Wagener, “Biliary glycoprotein, a potential human cell adhesion molecule, is down-regulated in colorectal carcinomas,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 22, pp. 10744–10748, 1993. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Tanaka, Y. Hinoda, H. Takahashi, H. Sakamoto, Y. Nakajima, and K. Imai, “Decreased expression of biliary glycoprotein in hepatocellular carcinomas,” International Journal of Cancer, vol. 74, no. 1, pp. 15–19, 1997. View at Google Scholar · View at Scopus
  13. R. Kammerer, R. Riesenberg, C. Weiler, J. Lohrmann, J. Schleypen, and W. Zimmermann, “The tumour suppressor gene CEACAM1 is completely but reversibly downregulated in renal cell carcinoma,” The Journal of Pathology, vol. 204, no. 3, pp. 258–267, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Busch, T. A. Hanssen, and C. Wagener, “Down-regulation of CEACAM1 in human prostate cancer: correlation with loss of cell polarity, increased proliferation rate, and Gleason grade 3 to 4 transition,” Human Pathology, vol. 33, no. 3, pp. 290–298, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Ortenberg, G. Galore-Haskel, I. Greenberg et al., “CEACAM1 promotes melanoma cell growth through Sox-2,” Neoplasia, vol. 16, no. 5, pp. 451–460, 2014. View at Publisher · View at Google Scholar
  16. A. Thies, I. Moll, J. Berger et al., “CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease,” Journal of Clinical Oncology, vol. 20, no. 10, pp. 2530–2536, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Markel, R. Ortenberg, R. Seidman et al., “Systemic dysregulation of CEACAM1 in melanoma patients,” Cancer Immunology, Immunotherapy, vol. 59, no. 2, pp. 215–230, 2009. View at Publisher · View at Google Scholar
  18. G. Markel, N. Lieberman, G. Katz et al., “CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity,” The Journal of Immunology, vol. 168, no. 6, pp. 2803–2810, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Markel, R. Seidman, N. Stern et al., “Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions,” Journal of Immunology, vol. 177, no. 9, pp. 6062–6071, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Markel, R. Seidman, Y. Cohen et al., “Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack,” Immunology, vol. 126, no. 2, pp. 186–200, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. G. Markel, H. Achdout, G. Katz et al., “Biological function of the soluble CEACAM1 protein and implications in TAP2-deficient patients,” European Journal of Immunology, vol. 34, no. 8, pp. 2138–2148, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Dráberová, H. Cerná, H. Brodská et al., “Soluble isoforms of CEACAM1 containing the A2 domain: Increased serum levels in patients with obstructive jaundice and differences in 3-fucosyl-N-acetyl-lactosamine moiety,” Immunology, vol. 101, no. 2, pp. 279–287, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Kuroki, F. Arakawa, Y. Matsuo, S. Oikawa, H. Nakazato, and Y. Matsuoka, “Three novel molecular forms of biliary glycoprotein deduced from cDNA clones from a human leukocyte library,” Biochemical and Biophysical Research Communications, vol. 176, no. 2, pp. 578–585, 1991. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Svenberg, B. Wahren, and S. Hammarstrom, “Elevated serum levels of a biliary glycoprotein (BGP I) in patients with liver or biliary tract disease,” Clinical & Experimental Immunology, vol. 36, no. 2, pp. 317–325, 1979. View at Google Scholar · View at Scopus
  25. Y. Kondo, Y. Hinoda, H. Akashi et al., “Measurement of circulating biliary glycoprotein (CD66a) in liver diseases,” Journal of Gastroenterology, vol. 36, no. 7, pp. 470–475, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. M. van der Flier, D. B. Sharma, S. Estevão et al., “Increased CD4(+) T cell co-inhibitory immune receptor CEACAM1 in neonatal sepsis and soluble-CEACAM1 in meningococcal sepsis: a role in sepsis-associated immune suppression?” PLoS ONE, vol. 8, no. 7, Article ID e68294, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Sivan, F. Suzan, O. Rona et al., “Serum CEACAM1 correlates with disease progression and survival in malignant melanoma patients,” Clinical and Developmental Immunology, vol. 2012, Article ID 290536, 8 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. D. M. Simeone, B. Ji, M. Banerjee et al., “CEACAM1, a novel serum biomarker for pancreatic cancer,” Pancreas, vol. 34, no. 4, pp. 436–443, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. B. M. Nolen, R. E. Brand, D. Prosser et al., “Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study,” PLoS ONE, vol. 9, no. 4, Article ID e94928, 2014. View at Publisher · View at Google Scholar
  30. D. Tilki, B. B. Singer, S. F. Shariat et al., “CEACAM1: a novel urinary marker for bladder cancer detection,” European Urology, vol. 57, no. 4, pp. 648–654, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. M.-Q. Zhou, Y. Du, Y.-W. Liu et al., “Clinical and experimental studies regarding the expression and diagnostic value of carcinoembryonic antigen-related cell adhesion molecule 1 in non-small-cell lung cancer,” BMC Cancer, vol. 13, article 359, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. M. J. Besser, R. Shapira-Frommer, A. J. Treves et al., “Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients,” Journal of Immunotherapy, vol. 32, no. 4, pp. 415–423, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. M. J. Besser, R. Shapira-Frommer, O. Itzhaki et al., “Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies,” Clinical Cancer Research, vol. 19, no. 17, pp. 4792–4800, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. I. Fernandez, A. Peña, N. Del Teso, V. Pérez, and J. Rodríguez-Cuesta, “Clinical biochemistry parameters in C57BL/6J mice after blood collection from the submandibular vein and retroorbital plexus,” Journal of the American Association for Laboratory Animal Science, vol. 49, no. 2, pp. 202–206, 2010. View at Google Scholar
  35. P. Vereecken, F. Cornelis, N. Van Baren, V. Vandersleyen, and J.-F. Baurain, “A synopsis of serum biomarkers in cutaneous melanoma patients,” Dermatology Research and Practice, vol. 2012, Article ID 260643, 7 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Solassol, A. Du-Thanh, T. Maudelonde, and B. Guillot, “Serum proteomic profiling reveals potential biomarkers for cutaneous malignant melanoma,” International Journal of Biological Markers, vol. 26, no. 2, pp. 82–87, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. H. M. Kluger, K. Hoyt, A. Bacchiocchi et al., “Plasma markers for identifying patients with metastatic melanoma,” Clinical Cancer Research, vol. 17, no. 8, pp. 2417–2425, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Ugurel, G. Rappl, W. Tilgen, and U. Reinhold, “Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival,” Journal of Clinical Oncology, vol. 19, no. 2, pp. 577–583, 2001. View at Google Scholar · View at Scopus
  39. I. Šamija, J. Lukač, J. Marić-Brozić et al., “Prognostic value of microphthalmia-associated transcription factor and tyrosinase as markers for circulating tumor cells detection in patients with melanoma,” Melanoma Research, vol. 20, no. 4, pp. 293–302, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Maier, R. P. Laubender, R. A. Sturm et al., “Osteopontin expression in plasma of melanoma patients and in melanocytic tumours,” Journal of the European Academy of Dermatology and Venereology, vol. 26, no. 9, pp. 1084–1091, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. H. Schmidt, J. S. Johansen, P. Sjoegren et al., “Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma,” Journal of Clinical Oncology, vol. 24, no. 5, pp. 798–804, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Kruijff, E. Bastiaannet, A. C. Muller Kobold, R. J. van Ginkel, A. J. H. Suurmeijer, and H. J. Hoekstra, “S-100B concentrations predict disease-free survival in stage III melanoma patients,” Annals of Surgical Oncology, vol. 16, no. 12, pp. 3455–3462, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. M. F. Sanmamed, O. Carranza-Rua, C. Alfaro et al., “Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins,” Clinical Cancer Research, vol. 20, no. 22, pp. 5697–5707, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. M. R. Becker, M. D. Siegelin, R. Rompel, A. H. Enk, and T. Gaiser, “COX-2 expression in malignant melanoma: a novel prognostic marker?” Melanoma Research, vol. 19, no. 1, pp. 8–16, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Nittka, C. Böhm, H. Zentgraf, and M. Neumaier, “The CEACAM1-mediated apoptosis pathway is activated by CEA and triggers dual cleavage of CEACAM1,” Oncogene, vol. 27, no. 26, pp. 3721–3728, 2008. View at Publisher · View at Google Scholar · View at Scopus